Rocket Lab (NASDAQ: RKLB) experienced a 7% decline in after-hours trading on Monday, as investors weighed the company's updated timeline for its Neutron rocket and a cautious margin outlook, which overshadowed a record-setting revenue quarter. The stock's slide came despite the company reporting a 62% year-over-year revenue surge to $234.1 million, an all-time high.
The mixed reaction highlights the growing divide in Rocket Lab's narrative. On one hand, demand and order backlog are expanding rapidly, with the company's backlog climbing to $2.36 billion, a 137% increase year-over-year. On the other hand, the path to the next major growth catalyst—the medium-lift Neutron rocket—remains uncertain, with management now targeting a fourth-quarter rollout to the launch pad, a shift from earlier expectations.
Quarterly Performance
For the second quarter of 2026, Rocket Lab reported revenue of $234.1 million, up from $144.5 million in the same period last year, beating analyst consensus of $231.6 million. Gross profit surged 82.3% to $84.6 million, with GAAP gross margin expanding to 36.1% from 32.1%. The company narrowed its net loss to $49.3 million from $66.4 million, and its adjusted EBITDA loss improved to $8.8 million from $27.6 million, reflecting significant operating leverage.
CEO Peter Beck touted the quarter as "another fantastic quarter," citing record results and strong momentum. However, he also acknowledged the narrowing window for a year-end Neutron launch, stating, "The window for an end-of-year launch is narrowing." The company now plans to roll out Neutron to the pad in the fourth quarter, but did not provide a revised flight schedule.
Margin Concerns and Guidance
Investor focus quickly shifted to the company's third-quarter guidance, which, while beating revenue expectations, fell short on margins. Rocket Lab projects Q3 revenue in the range of $250 million to $265 million, above the consensus estimate of $238.5 million. However, the company anticipates a GAAP gross margin between 29% and 31%, significantly below the analyst consensus of 37.6%. Adjusted EBITDA loss is expected to be between $17 million and $23 million, wider than the $10 million loss analysts had projected.
CFO Adam Spice attributed the margin pressure to product mix, noting that a larger proportion of revenue is coming from space systems, which carry lower margins, and a decline in sales of established products. This mix shift is likely to persist as the company scales its satellite manufacturing operations.
Balance Sheet Strength
Rocket Lab's balance sheet remains robust, with cash and equivalents totaling $2.13 billion as of June 30, 2026, up 157% from the end of 2025. The company's equity base also expanded to $3.49 billion, though this came at the cost of dilution, with common shares outstanding increasing 10% to 598.2 million over the past six months. The funding buffer reduces immediate financing risk, but execution risk remains, as Neutron still needs to pass integrated tests and demonstrate consistent performance.
Demand and Backlog
Despite the near-term challenges, demand for Rocket Lab's launch services remains robust. The company signed new launch contracts during and after the quarter exceeding $437 million, including optional agreements, bringing its launch backlog to over 90 missions. This strong demand underscores the market's need for a reliable medium-lift vehicle, a niche Neutron aims to fill.
Market Reaction and Outlook
Shares closed Monday's regular session at $78.37, but the after-hours decline is provisional until Tuesday's open. The market's reaction underscores the high stakes surrounding Neutron's successful deployment. Investors are looking for physical evidence of progress—a rocket on the pad in Q4 and a credible flight date that maintains reliability.
Risks remain, including potential further delays or additional investment requirements for Neutron, as well as margin pressures from a satellite-heavy revenue mix. Additionally, the timing of major government contracts could be inconsistent, adding uncertainty to future revenue streams.
As Rocket Lab navigates this critical phase, the company's ability to execute on Neutron will be pivotal in determining whether its stock can regain upward momentum.
